Marker Therapeutics Inc (MRKR)

[microcapbiotech]

Well, now that the merger is done, it looks like the combined market cap will be about 380 Million.
The two "equals", Tapimmune and Marker stockholders own about 210 Million (55%), and private stockholders own about 170 Million (45%).
The MRKR share price would have to go up to about $22 to get to a 1 Billion dollar market cap.
Gilead bought Kite for about 12 Billion.
The new Allogene is almost 3 Billion.
MRKR price should be going up higher as more fund money flows in, but even if it doubles, it would still seem kind of cheap compared to others.